A Phase 1 interventional study of lurbinectedin (PM01183) and Doxorubicin in Endometrial Adenocarcinomas, Neuroendocrine Tumors and Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy, sponsored by PharmaMar. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-03-09.
Sponsored by PharmaMar · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Neuroendocrine Tumors with a site in Spain — 9 open to participants now, 16 under way, 7 of them phase 3. Neuroendocrine Tumors · Spain.
Among the 43 studies in Neuroendocrine Tumors with a site in Spain, this one is the 22nd largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2011, is one of 2 in phase 1, and was the 15th registered.
543 studies on the registry are indexed under Neuroendocrine Tumors; 135 are open to participants now.
Browse Neuroendocrine Tumors studies →9 of the 43 studies in Neuroendocrine Tumors with a site in Spain are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Spain, United States, Brazil and 6 more countries
Ages 18+
ITM Solucin GmbH · Sites in Spain, United States, France
Ages 24 mo–18 yrs
Exelixis · Sites in Spain, United States, Australia and 15 more countries
Ages 18+
Grupo Espanol de Tumores Neuroendocrinos · Sites in Spain, France
Ages 18+
Fundación de investigación HM · Sites in Spain
Ages 3+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 21 · Phase 3 12 · Phase 4 3
First in 2006; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 41 across 387 interventional studies indexed under Neuroendocrine Tumors.
Median enrollment 141 across the 37 interventional studies, 400 across the 6 observational. Of the 26 that completed or were terminated, 22 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 43 have an industry lead sponsor. The 10 most frequent:
PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
PharmaMar has 2 studies filed under Neuroendocrine Tumors — fewer than ten, so there is no comparison to draw.
7 of the studies in Neuroendocrine Tumors with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477576Phase 3RayzeBio, Inc.Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | 2026-12 |
| NCT04919226Phase 3ITM Solucin GmbHLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE | 2027-06 |
| NCT07087054Phase 3Crinetics Pharmaceuticals Inc.Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | 2027-08 |
| NCT07903532Instituto de Investigación Sanitaria de la Fundación Jiménez DíazMulticenter Study for External Validation of the TB-NET Score | 2027-03 |
| NCT02568267Hoffmann-La RocheBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 43 studies in Neuroendocrine Tumors with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination with Fixed Doxorubicin in Non- Heavily Pretreated Patients with Selected Advanced Solid Tumors to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with doxorubicin, to characterize the safety profile and feasibility of this combination, to characterize the pharmacokinetics (PK) of this combination, to obtain preliminary information on the clinical antitumor activity,to explore the feasibility, safety and efficacy of a potential improvable dose of this combination in selected tumor types [i.e. small cell lung cancer (SCLC) and endometrial cáncer] and to evaluate the pharmacogenomics (PGx) in tumor samples of patients exposed to PM01183 and doxorubicin at the RD in order to assess potential markers of response and/or resistance.
The study has currently met its primary end point and is now recruiting patients to be treated at the RD expansion cohort of selected tumor types, specifically: endometrial adenocarcinomas, neuroendocrine tumors, and small-cell lung cancer (SCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with a histologically/ confirmed diagnosis of advanced disease of any of the following tumors:
Exclusion Criteria:
Concomitant diseases/conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: lurbinectedin (PM01183) · Drug: Doxorubicin
lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
Maximum Tolerated Dose (MTD)
A minimum of three patients will be included at each DL. If no patients experience a DLT during Cycle 1, the dose will be escalated. If one of three patients experiences a DLT, three additional patients will be included at that level. If \>1 evaluable patient during dose escalation at a given DL experience a DLT during Cycle 1, that DL will be considered the MTD and dose escalation will be terminated, except if all DLTs are related to neutropenia exclusively, in which case dose escalation may be resumed as originally planned in a new cohort of patients but with compulsory primary G-CSF prophylaxis.
Time frame: During the first cycle of treatment, up to 28 days
Recommended Dose (RD)
The DL immediately below the MTD, or DL4 if the MTD is not yet defined during dose escalation before the last DL (i.e., DL4) is reached, was to be initially expanded up to a minimum of nine evaluable patients. If less than three among the first nine evaluable patients treated within the expansion cohort experience a DLT during Cycle 1, this DL will be the RD.
Time frame: During the first cycle of treatment, up to 28 days
Number of Participants With Dose-limiting Toxicities
DLT,dose-limiting toxicity Patients enrolled into this study were originally not allowed to receive primary G-CSF prophylaxis. However, the finding of dose-limiting febrile neutropenia in two patients treated at dose level I in the present study (see below) suggested that increasing doses of the DOX/PM01183 combination might require primary G-CSF prophylaxis to decrease the risk of febrile neutropenia. Therefore, a separate dose escalation was established to define the MTD and the RD of the DOX/PM01183 combination with compulsory primary G-CSF prophylaxis.
Time frame: During the first cycle of treatment, up to 28 days
Best Overall Tumor Response
Tumor response was evaluated according to the RECIST v.1.1 for target lesions and assessed by computed tomography (CT) scans or magnetic resonance imagings (MRIs): Progressive disease (PD) is declared when there is an increase in sum of target disease ≥ 20%, stable diease (SD) when the change is \> -30% and ≤ 20%, partial response (PR) when there is a decrease in sum of target disease ≥ 30%, and complete response (CR) when all lesions have disappeared or all lesions have disapeared and all nodal disease is \< 10 mm each.
Time frame: Tumor assessments were done every six weeks up to study completion
Duration of Response
The duration of overall response was measured from the time measurement criteria are met for complete response (CR)/ PR, whichever is first recorded, until the first date in which progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started) or the date of death. In absence of disease progression or death, the duration of response was censored on the date of last tumor evaluation.
Time frame: Time from the time measurement criteria are met for complete response, whichever is first recorded, until the first date in which progressive disease is objectively documented or the date of death, assessed up to 72 months
Progression-free Survival
Progression-free survival (PFS) is defined as the time from the date of first infusion of study treatment to the date of progression or death (due to any cause). If progression or death has not occurred at the time of the analysis, the PFS was censored on the date of last tumor evaluation.
Time frame: Time from the date of first administration to the date of PD or death (of any cause), whichever came first, assessed up to 72 months
Overall Survival
Overall survival (OS) is defined as the time from the date of first infusion of study treatment to the date of death (due to any cause). Patients with no documented death were censored at the last date they are known to be alive
Time frame: Time from the date of first administration to the date of death (of any cause), assessed up to 72 months
122 patients were enrolled at 7 sites. 120 patients were treated with DOX/PM01183 combination: 73 Cohort A (DOX \[mg/m2\]+PM01183 \[mg FD\]) \& 47 Cohort B (DOX \[mg/m2\]+PM01183 \[mg/m2\]). Patients participated between 25May2011-9Aug2017 (last followup). First dose of the first cycle was given on 13Jun2011 and last dose of the last cycle on 19Jul2017
| Milestone | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial |
|---|---|---|---|
| Started | 73 | 28 | 19 |
| Completed | 0 | 0 | 0 |
| Not completed | 73 | 28 | 19 |
| Withdrew: Non-treatment-related ae | 0 | 0 | 1 |
| Withdrew: Progressive disease | 55 | 23 | 10 |
| Withdrew: Treatment delay over protocol | 0 | 0 | 1 |
| Withdrew: Physician decision | 7 | 2 | 0 |
| Withdrew: Clinical progression | 0 | 1 | 1 |
| Withdrew: End of study | 2 | 0 | 2 |
| Withdrew: Adverse event | 0 | 2 | 1 |
| Withdrew: Treatment-related ae | 4 | 0 | 2 |
| Withdrew: Withdrawal by subject | 4 | 0 | 1 |
| Withdrew: Clinical deterioration | 1 | 0 | 0 |
A minimum of three patients will be included at each DL. If no patients experience a DLT during Cycle 1, the dose will be escalated. If one of three patients experiences a DLT, three additional patients will be included at that level. If \>1 evaluable patient during dose escalation at a given DL experience a DLT during Cycle 1, that DL will be considered the MTD and dose escalation will be terminated, except if all DLTs are related to neutropenia exclusively, in which case dose escalation may be resumed as originally planned in a new cohort of patients but with compulsory primary G-CSF prophylaxis.
| DOX mg/m2 PM01183 mg FD | Patients Without Primary G-CSF Prophylaxis | Patients With Primary G-CSF Prophylaxis |
|---|---|---|
| Doxorubicin | 50 | 50 |
| PM01183 | 5.0 | 5.0 |
The DL immediately below the MTD, or DL4 if the MTD is not yet defined during dose escalation before the last DL (i.e., DL4) is reached, was to be initially expanded up to a minimum of nine evaluable patients. If less than three among the first nine evaluable patients treated within the expansion cohort experience a DLT during Cycle 1, this DL will be the RD.
| DOX mg/m2 PM01183 mg FD | Patients Without Primary G-CSF Prophylaxis |
|---|---|
| Doxorubicin | 50 |
| PM01183 | 4.0 |
DLT,dose-limiting toxicity Patients enrolled into this study were originally not allowed to receive primary G-CSF prophylaxis. However, the finding of dose-limiting febrile neutropenia in two patients treated at dose level I in the present study (see below) suggested that increasing doses of the DOX/PM01183 combination might require primary G-CSF prophylaxis to decrease the risk of febrile neutropenia. Therefore, a separate dose escalation was established to define the MTD and the RD of the DOX/PM01183 combination with compulsory primary G-CSF prophylaxis.
| Participants | Cohort A: Dose I Without Primary G-CSF Prophylaxis | Cohort A: Dose II Without Primary G-CSF Prophylaxis | Cohort A: Dose I Without Primary G-CSF Proph and Age Limit | Cohort A: Dose III Without Primary G-CSF Prophylaxis | Cohort A: Dose IV Without Primary G-CSF Prophylaxis | Cohort A: Dose I With Primary G-CSF Prophylaxis | Cohort A: Dose III With Primary G-CSF Prophylaxis | Cohort A: Dose IV With Primary G-CSF Prophylaxis | Cohort B: DOX [mg/m2] Plus PM01183 [mg/m2] |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities | 2 | 0 | 0 | 8 | 2 | 0 | 0 | 2 | 4 |
Tumor response was evaluated according to the RECIST v.1.1 for target lesions and assessed by computed tomography (CT) scans or magnetic resonance imagings (MRIs): Progressive disease (PD) is declared when there is an increase in sum of target disease ≥ 20%, stable diease (SD) when the change is \> -30% and ≤ 20%, partial response (PR) when there is a decrease in sum of target disease ≥ 30%, and complete response (CR) when all lesions have disappeared or all lesions have disapeared and all nodal disease is \< 10 mm each.
| Participants | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial |
|---|---|---|---|
| CR | 7 | 1 | 0 |
| PR | 19 | 9 | 8 |
| SD≥4 months | 13 | 4 | 4 |
| SD<4 months | 11 | 6 | 3 |
| PD | 22 | 8 | 4 |
The duration of overall response was measured from the time measurement criteria are met for complete response (CR)/ PR, whichever is first recorded, until the first date in which progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started) or the date of death. In absence of disease progression or death, the duration of response was censored on the date of last tumor evaluation.
| months | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial |
|---|---|---|---|
| Duration of Response | 7.2 (3.4 to 8.6) | 5.2 (1 to 6.9) | 7.5 (6.4 to NA) |
Progression-free survival (PFS) is defined as the time from the date of first infusion of study treatment to the date of progression or death (due to any cause). If progression or death has not occurred at the time of the analysis, the PFS was censored on the date of last tumor evaluation.
| months | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial |
|---|---|---|---|
| Progression-free Survival | 3.8 (2.6 to 5.3) | 3.3 (1.4 to 6.2) | 7.7 (2.0 to 16.7) |
Overall survival (OS) is defined as the time from the date of first infusion of study treatment to the date of death (due to any cause). Patients with no documented death were censored at the last date they are known to be alive
| months | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial |
|---|---|---|---|
| Overall Survival | 36.9 (15.1 to NA) | 7.9 (4.2 to 11.5) | 14.2 (4.5 to NA) |
Collected over Participants were assessed through study completion, approximately 6 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A | 15/73 (20.5%) | 47/73 (64.4%) | 73/73 (100%) |
| Cohort B: SCLC 2nd Line | 22/28 (78.6%) | 19/28 (67.9%) | 28/28 (100%) |
| Cohort B: Endometrial | 11/19 (57.9%) | 14/19 (73.7%) | 18/19 (94.7%) |
| Event | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 25/73 | 4/28 | 4/19 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/73 | 4/28 | 0/19 |
| NeutropeniaBlood and lymphatic system disorders | 9/73 | 2/28 | 1/19 |
| Deep vein thrombosisVascular disorders | 1/73 | 0/28 | 2/19 |
| VomitingGastrointestinal disorders | 2/73 | 2/28 | 1/19 |
| Decreased appetiteMetabolism and nutrition disorders | 0/73 | 2/28 | 0/19 |
| HyponatraemiaMetabolism and nutrition disorders | 0/73 | 2/28 | 0/19 |
| Lung infectionInfections and infestations | 0/73 | 2/28 | 0/19 |
| PneumoniaInfections and infestations | 3/73 | 2/28 | 0/19 |
| AnaemiaBlood and lymphatic system disorders | 4/73 | 0/28 | 0/19 |
| Event | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial |
|---|---|---|---|
| FatigueGeneral disorders | 66/73 | 25/28 | 17/19 |
| NauseaGastrointestinal disorders | 45/73 | 19/28 | 14/19 |
| Decreased appetiteMetabolism and nutrition disorders | 44/73 | 16/28 | 6/19 |
| AnaemiaBlood and lymphatic system disorders | 39/73 | 7/28 | 5/19 |
| AlopeciaSkin and subcutaneous tissue disorders | 38/73 | 7/28 | 10/19 |
| CoughRespiratory, thoracic and mediastinal disorders | 30/73 | 14/28 | 6/19 |
| ConstipationGastrointestinal disorders | 33/73 | 10/28 | 9/19 |
| DiarrhoeaGastrointestinal disorders | 30/73 | 3/28 | 9/19 |
| VomitingGastrointestinal disorders | 26/73 | 12/28 | 9/19 |
| Mucosal inflammationGeneral disorders | 34/73 | 5/28 | 5/19 |
| Age, Categorical(Participants) | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial | Total |
|---|---|---|---|---|
| Age — <=18 years | 0 | 0 | 0 | 0 |
| Age — Between 18 and 65 years | 53 | 18 | 8 | 79 |
| Age — >=65 years | 20 | 10 | 11 | 41 |
| Age, Continuous(years) | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial | Total |
|---|---|---|---|---|
| Median | 62.2 (22 to 78) | 64 (49 to 77) | 66 (55 to 73) | 62.2 (22 to 78) |
| Sex: Female, Male(Participants) | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial | Total |
|---|---|---|---|---|
| Female | 38 | 7 | 19 | 64 |
| Male | 35 | 21 | 0 | 56 |
| Race/Ethnicity, Customized(Participants) | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial | Total |
|---|---|---|---|---|
| Race : Caucasian | 72 | 27 | 19 | 118 |
| Race : Asian/oriental | 1 | 0 | 0 | 1 |
| Race : Black | 0 | 1 | 0 | 1 |
| ECOG PS(Participants) | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial | Total |
|---|---|---|---|---|
| PS 0 | 27 | 9 | 6 | 42 |
| PS 1 | 46 | 19 | 12 | 77 |
| PS 2 | 0 | 0 | 1 | 1 |
| Tumor type(Participants) | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial | Total |
|---|---|---|---|---|
| SCLC 2 line | 22 | 28 | 0 | 50 |
| SCLC 3 line | 6 | 0 | 0 | 6 |
| Endometrial | 15 | 0 | 19 | 34 |
| NET-GEP | 8 | 0 | 0 | 8 |
| STS | 8 | 0 | 0 | 8 |
| Bladder | 5 | 0 | 0 | 5 |
| Gastric | 4 | 0 | 0 | 4 |
| Breast | 3 | 0 | 0 | 3 |
| Ovarian | 1 | 0 | 0 | 1 |
| HCC | 1 | 0 | 0 | 1 |
| Lines of prior anticancer therapies(Participants) | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial | Total |
|---|---|---|---|---|
| 0 lines | 12 | 0 | 3 | 15 |
| 1 line | 42 | 27 | 11 | 80 |
| 2 lines | 16 | 1 | 5 | 22 |
| 3 lines | 2 | 0 | 0 | 2 |
| >3 lines | 1 | 0 | 0 | 1 |
| Body surface area(m^2) | Cohort A | Cohort B: SCLC 2nd Line | Cohort B: Endometrial | Total |
|---|---|---|---|---|
| Median | 1.8 (1.3 to 2.3) | 1.9 (1.5 to 2.3) | 1.8 (1.6 to 2.3) | 1.8 (1.3 to 2.3) |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2011 to primary completion in Aug 2017, 74 months.
Results were first posted in Mar 2020, 2 years 7 months after primary completion.
Of 54 phase 1 interventional studies under Neuroendocrine Tumors, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 75. This study's 74 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PM 01183